Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | ASPH | Q12797 | 1/20 | 0.41 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 11/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.38 |
| ▸ | CD38 | P28907 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28311764 | 0.85 | HTT (0.45) | HTTHSD17B10KDM4EASPHKDM8 | |
| SCHEMBL1720696 | 0.84 | ASPH (0.59) | L3MBTL1HTTHSD17B10KDM4EASPH | |
| SCHEMBL29882303 | 0.84 | ASPH (0.59) | L3MBTL1HTTHSD17B10KDM4EASPH | |
| SCHEMBL25251294 | 0.82 | L3MBTL1 (0.46) | L3MBTL1HTTHSD17B10KDM4EKMT2A | |
| SCHEMBL30238408 | 0.82 | L3MBTL1 (0.46) | L3MBTL1HTTHSD17B10KDM4EASPH | |
| SCHEMBL17509160 | 0.82 | P2RX7 (0.42) | HTTHSD17B10KDM4EASPHKDM8 | |
| SCHEMBL9928615 | 0.82 | SLC6A9 (0.42) | L3MBTL1HTTHSD17B10KDM4EASPH | |
| SCHEMBL17981949 | 0.81 | L3MBTL1 (0.44) | L3MBTL1HTTHSD17B10KDM4EP2RX7 | |
| SCHEMBL18417648 | 0.79 | KDM4E (0.44) | L3MBTL1HTTKDM4EASPHKDM8 | |
| SCHEMBL31726092 | 0.78 | SLC6A9 (0.45) | HTTHSD17B10KDM4EASPHKDM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2406265-A2 | SUBSTITUTED 3-AMINOISOXAZOLOPYRIDINES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2012-01-18 | — | — | EP | disclosed |
| WO-2010102778-A2 | SUBSTITUTED 3-AMINOISOXAZOLOPYRIDINES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2010-09-16 | — | — | WO | disclosed |
| US-20100234419-A1 | SUBSTITUTED 3-AMINOISOXAZOLOPYRIDINES AS KCNQ2/3 MODULATORS | GRUNENTHAL GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234419-A1 | SUBSTITUTED 3-AMINOISOXAZOLOPYRIDINES AS KCNQ2/3 MODULATORS | KCNQ1, KCNQ2, KCNQ3 | L3MBTL1 4399/4885HTT 2804/4885HSD17B10 4203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.